Havana, Nov 6 – The production of vaccines and therapeutic antibodies for the treatment of cancer, technological challenges, how to improve access to immunotherapy, among other issues, make up the scientific agenda of an event that will be opened today in Havana.
The meeting, to be run until Nov. 8 at this capital’s Palco Hotel, is organized by the Center of Molecular Immunology (CIM).
Experts from Cuba, Brazil, Israel, France, Japan, Argentina, who will also talk on the regulation and product development, will also participate in this event.
The benefits of VAXIRA, a new immunotherapeutic agent in treating non-small-cell lung cancer, will be also analyzed in the forum.
For many years, the CIM is intensively working on the development of several compounds, some of which are already recognized for their benefits and low toxicity.
This is the case of CIMAher, trade name of Nimotuzumab, a humanized immunoglobulin that has demonstrated a potent anti-angiogenic effect, and is indicated in combination with radiotherapy in the treatment of head and neck tumors in advanced stages.
Source: Prensa Latina